WHO WANTS TO BE AN EYECARE MILLIONAIRE?

THE INTREPID EDITION

Thursday, November 7, 2024

6:30 PM to 8:00 PM ET

Indianapolis Artsgarden at 110 W Washington St, Indianapolis, IN 46204

Available for Live Stream

1.5 AMA PRA Category 1 Credits™

Join us for an educational and entertaining evening inspired by the popular game show format of Who Wants to be a Millionaire? During our show, attendees will participate in a dynamic, interactive learning experience where leading eyecare professionals tackle pressing issues in the field. This engaging format will involve audience participation, providing attendees a unique opportunity to test their knowledge and learn through real-time discussions and expert insights. Don’t miss this chance to enhance your clinical practice while enjoying a spirited competition among peers!

COPE Accreditation Pending

This activity is supported by an unrestricted educational grant from Apellis Pharmaceuticals, Inc., LENZ Therapeutics, Tarsus Pharmaceuticals, Inc., Topcon Healthcare, Inc., and Viatris, Inc.

FACULTY

Jacob Lang, OD, FAAO(Host and Program Chair)

Nathan Lighthizer, OD, FAAO

Daniel Epshtein, OD, FAAO

Carolyn Majcher, OD, FAAO

Selina McGee, OD, FAAO

Justin Schweitzer, OD, FAAO

Mark E. Schaeffer, OD, FAAO

Vin T. Dang, OD, FAAO

Damon Dierker, OD, FAAO

AGENDA & TOPICS

6:30 PM

6:40 PM

6:55 PM

7:10 PM

7:25 PM

7:40 PM

8:00 PM

Welcome and Introduction

Presbyopia

Demodex blepharitis

Glaucoma

Retina

Summary and Evaluation

Conclude

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Fundingsland Group and the Intrepid Eye Society. The Fundingsland Group is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Fundingsland Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES

  1. Describe the role of Demodex blepharitis and integrate treatment protocols based on the patients’ characteristics and the safety and efficacy of treatment. 

  2. Assess the risks and benefits of current treatments for glaucoma and employ strategies to select the most appropriate treatment strategy for patients. 

  3. Describe modern screening protocols for dry AMD/GA for earlier detection and integrate the evidence-based diagnostics tools and criteria into practice. 

  4. Explain the mechanisms of action for current and emerging non-surgical treatments for presbyopia, analyze published clinical trial data, and identify ideal patient candidates for each treatment option.

  5. Integrate updated referral timing and criteria into practice.

COPE Accreditation Pending

This activity is supported by an unrestricted educational grant from Apellis Pharmaceuticals, Inc., LENZ Therapeutics, Tarsus Pharmaceuticals, Inc., Topcon Healthcare, Inc., and Viatris, Inc.

Faculty Disclosures


Financial Relationship Disclosures

It is the policy of TFG that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. All identified relevant financial relationships have been mitigated and the educational content thoroughly evaluated for fair, balanced, and safe, effective patient care.


Vin Dang, OD, FAAO, Faculty, has the following financial relationships: Advisory Board: Aerie, Abbott Medical Optics, Avelino, Eyenovia, Eye Vance, Horizon, Tarsus. Advisory Board & Speaker: Allergan/AbbVie, Bausch & Lomb, Bio-Tissue, Dompe, Kala, Johnson & Johnson, Novartis, Sight Sciences, Sun Pharmaceutical, Viatris, and Zeiss. Speaker: Harrow Therapeutics, Nova Bay, and Science Based Health.


Damon Dierker, OD, FAAO, Faculty, has the following financial relationships: Advisory Board: Aerie, Alcon, Avellino, Azura, Bausch & Lomb, Bio-Tissue, Eyes on Eyecare, Eye Vance, Genentech, Glaukos, Immunogen, Kala, Macu Logix, Notal Vision, Novartis, Ocular Therapeutix, Ocuphire, Occu Terra, Oyster Point, Quidel, RVL Pharmaceuticals, Shire, Sight Sciences, Sun Pharmaceutical, Tarsus, Thea Pharma, and Zeiss. Consultant: Nova Bay, Quidel, Scope, Tear Lab, Thea Pharma and Trukera Medical. Consultant and Speaker: Alcon, Bio-Tissue, Eye Vance, Glaukos, Johnson & Johnson, Kala, Lumenis, Macu Logix, Notal Vision, Novartis, Oyster Point, RVL Pharmaceuticals, Science Based Health, Shire, Sight Sciences, and Tarsus. Research: Arctic DX, Bio-Tissue, Gyroscope, Notal Vision, Ocular Therapeutix, Oyster Point, Sight Sciences, and Tarsus. Speaker: Apellis, Bausch & Lomb, Macu Health, Optovue, Osmotic Pharmaceuticals, and Sun Pharmaceutical.


Daniel Epshtein, OD, FAAO, Faculty, has the following financial relationships: Consultant: Immunogen, Iveric Bio, and Zeiss. Speaker: Tarsus.


Jacob Lang, OD, FAAO, Host & Program Chair, has the following financial relationships: Consultant: Allergan, AOS, Avellino, Dompe, Horizon, Kala, Novartis, Orasis, Oyster Point, Quidel, Sun Pharmaceutical, and Tarsus. Speaker: Sun Pharmaceutical.


Nathan Lightizer, OD, FAAO, Faculty, has the following financial relationships: Advisory Board: Aerie, Bruder, Eyepromise, Horizon, Ivantis, Novartis, Orasis, Oyster Point, Sight Sciences, Tarsus, and Thea Pharma. Advisory Board. Consultant: LKC, Ocusoft and Orasis. Consultant & Speaker: Bausch & Lomb, Diopsys, Reichert, and Virtual Vision. Speaker: Allergan, Avellino, Dompe, Ellex, iCare, Innova Systems, Lumenis, Nidex, Novartis, Optovue, RVL Pharmaceutical, Sight Sciences, Sun Pharmaceutical and TRIAD Ophthalmics.


Carolyn Majcher, OD, FAAO, Faculty, has the following financial relationships: Consultant: Apellis, LENZ Therapeutics, Notal Vision, Ocuterra, Optomed, Tarsus, and Zeiss. Consultant & Speaker: Iveric Bio, Regeneron, and Zeiss.


Selina McGee, OD, FAAO, Faculty, has the following financial relationships: Consultant: Alcon, Aldeyra, Bruder, Horizon, and Novartis. Consultant & Speaker: Allergan, Avellino, Bausch & Lomb, Cynosure, and Dompe.


Mark Schaeffer, OD, FAAO, Faculty, has the following financial relationships: Consultant: Allergan, Cooper Vision, LENZ Therapeutics, Optase, Science Based Health, Sight Sciences, and Zeiss. Consultant & Speaker: Alcon, Bausch & Lomb, and Tarsus.


Justin Schweitzer, OD, FAAO, Faculty, has the following financial relationships: Consultant: Aldeyra, Avellino, Bruder, Eyenovia, Heru, Iveric Bio, Medi Print, Reichert, Science Based Health, Thea Pharma, Viatris, and Visus. Consultant & Speaker: Alcon, Allergan, Bausch & Lomb, Dompe, Glaukos, LKC, Sight Sciences, Sun Pharmaceutical, Tarsus, and Zeiss.


TFG staff and planners have no financial relationships with ineligible companies.

The Fundingsland Group (TFG) is an independent medical education company that believes in providing compelling, compliant, and effective peer-to-peer education that addresses gaps in clinical knowledge, opinions, and practice patterns. Through a unique, data-driven process, TFG identifies key educational needs and evaluates progress towards meeting clearly defined goals. By strategically collaborating with education partners and industry experts, we create customized education programs that seek to change opinions, affect practice patterns and, ultimately, improve patient care. 

© 2024 The Fundingsland Group. All rights reserved.